ProQR Announces Second Quarter 2022 Operating and Financial Results Press release ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial w August 04, 2022